GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (CHIX:IPNp) » Definitions » Beneish M-Score

Ipsen (CHIX:IPNP) Beneish M-Score : -2.26 (As of Dec. 12, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Ipsen Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.26 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ipsen's Beneish M-Score or its related term are showing as below:

CHIX:IPNp' s Beneish M-Score Range Over the Past 10 Years
Min: -3.1   Med: -2.63   Max: -2.26
Current: -2.26

During the past 13 years, the highest Beneish M-Score of Ipsen was -2.26. The lowest was -3.10. And the median was -2.63.


Ipsen Beneish M-Score Historical Data

The historical data trend for Ipsen's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Beneish M-Score Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.10 -2.88 -2.52 -2.62 -2.26

Ipsen Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.62 - -2.26 -

Competitive Comparison of Ipsen's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipsen's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ipsen's Beneish M-Score falls into.



Ipsen Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ipsen for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.977+0.528 * 1.0067+0.404 * 1.2971+0.892 * 1.0475+0.115 * 2.763
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0426+4.679 * -0.035031-0.327 * 0.8784
=-2.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was €687 Mil.
Revenue was €3,306 Mil.
Gross Profit was €2,735 Mil.
Total Current Assets was €1,898 Mil.
Total Assets was €6,323 Mil.
Property, Plant and Equipment(Net PPE) was €575 Mil.
Depreciation, Depletion and Amortization(DDA) was €88 Mil.
Selling, General, & Admin. Expense(SGA) was €1,135 Mil.
Total Current Liabilities was €1,627 Mil.
Long-Term Debt & Capital Lease Obligation was €270 Mil.
Net Income was €644 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €866 Mil.
Total Receivables was €671 Mil.
Revenue was €3,157 Mil.
Gross Profit was €2,629 Mil.
Total Current Assets was €2,398 Mil.
Total Assets was €5,615 Mil.
Property, Plant and Equipment(Net PPE) was €581 Mil.
Depreciation, Depletion and Amortization(DDA) was €337 Mil.
Selling, General, & Admin. Expense(SGA) was €1,039 Mil.
Total Current Liabilities was €1,335 Mil.
Long-Term Debt & Capital Lease Obligation was €582 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(686.5 / 3306.4) / (670.8 / 3156.5)
=0.207628 / 0.212514
=0.977

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2628.8 / 3156.5) / (2735.2 / 3306.4)
=0.832821 / 0.827244
=1.0067

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1898.4 + 574.6) / 6322.9) / (1 - (2397.6 + 581.4) / 5614.6)
=0.608882 / 0.469419
=1.2971

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3306.4 / 3156.5
=1.0475

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(336.5 / (336.5 + 581.4)) / (87.9 / (87.9 + 574.6))
=0.366598 / 0.132679
=2.763

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1134.9 / 3306.4) / (1039.2 / 3156.5)
=0.343243 / 0.329225
=1.0426

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((269.7 + 1626.8) / 6322.9) / ((581.8 + 1335.4) / 5614.6)
=0.299941 / 0.341467
=0.8784

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(644.4 - 0 - 865.9) / 6322.9
=-0.035031

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ipsen has a M-score of -2.26 suggests that the company is unlikely to be a manipulator.


Ipsen Business Description

Traded in Other Exchanges
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Ipsen Headlines

No Headlines